PYXS vs. CDTX, CYRX, IVA, AURA, CMPX, TRDA, IMMP, HRTX, PHAT, and GOSS
Should you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Cidara Therapeutics (CDTX), Cryoport (CYRX), Inventiva (IVA), Aura Biosciences (AURA), Compass Therapeutics (CMPX), Entrada Therapeutics (TRDA), Immutep (IMMP), Heron Therapeutics (HRTX), Phathom Pharmaceuticals (PHAT), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry.
Pyxis Oncology vs.
Cidara Therapeutics (NASDAQ:CDTX) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, community ranking, institutional ownership, media sentiment, dividends, valuation and profitability.
Pyxis Oncology has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -289.05%. Pyxis Oncology's return on equity of -36.22% beat Cidara Therapeutics' return on equity.
Cidara Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.
Cidara Therapeutics has higher earnings, but lower revenue than Pyxis Oncology. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Cidara Therapeutics received 433 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 81.58% of users gave Pyxis Oncology an outperform vote while only 70.52% of users gave Cidara Therapeutics an outperform vote.
Cidara Therapeutics presently has a consensus target price of $41.86, suggesting a potential upside of 84.64%. Pyxis Oncology has a consensus target price of $9.00, suggesting a potential upside of 637.70%. Given Pyxis Oncology's higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than Cidara Therapeutics.
35.8% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 3.9% of Cidara Therapeutics shares are owned by company insiders. Comparatively, 10.6% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Cidara Therapeutics had 5 more articles in the media than Pyxis Oncology. MarketBeat recorded 9 mentions for Cidara Therapeutics and 4 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.79 beat Cidara Therapeutics' score of 0.75 indicating that Pyxis Oncology is being referred to more favorably in the news media.
Summary
Pyxis Oncology beats Cidara Therapeutics on 11 of the 19 factors compared between the two stocks.
Get Pyxis Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pyxis Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:PYXS) was last updated on 6/2/2025 by MarketBeat.com Staff
Buy PYXS Stock Free PYXS Stock Alerts